Oncolytics Biotech (ONCY) Cash & Equivalents (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Cash & Equivalents data on file, last reported at $5.2 million in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 54.42% year-over-year to $5.2 million in Q4 2025; TTM through Dec 2025 was $5.2 million, a 54.42% decrease from a year earlier, with the FY2025 full-year figure at $5.2 million, down 53.05% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $5.2 million, down from $9.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ONCY reached as high as $41.3 million in Q2 2021 and fell as low as $5.2 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $21.2 million across 5 years, with a median of $20.1 million in 2024.
• Across the five-year window, Cash & Equivalents tumbled 73.75% in 2022 and surged 198.38% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $32.7 million in 2021, then tumbled by 73.75% to $8.6 million in 2022, then jumped by 198.38% to $25.6 million in 2023, then sank by 55.5% to $11.4 million in 2024, then slumped by 54.42% to $5.2 million in 2025.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $5.2 million in Q4 2025, $9.0 million in Q3 2025, and $10.6 million in Q2 2025.